The YfkO nitroreductase from bacillus licheniformis on gold-coated superparamagnetic nanoparticles: towards a novel directed enzyme prodrug therapy approach

Ball, Patrick, Hobbs, Robert, Anderson, Simon, Thompson, Emma, Gwenin, Vanessa, Von Ruhland, Christopher and Gwenin, Christopher 2021. The YfkO nitroreductase from bacillus licheniformis on gold-coated superparamagnetic nanoparticles: towards a novel directed enzyme prodrug therapy approach. Pharmaceutics 13 (4) , 517. 10.3390/pharmaceutics13040517

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (3MB) | Preview

Abstract

The bacterial nitroreductase NfnB has been the focus of a great deal of research for its use in directed enzyme prodrug therapy in combination with the nitroreductase prodrug CB1954 with this combination of enzyme and prodrug even entering clinical trials. Despite some promising results, there are major limitations to this research, such as the fact that the lowest reported Km for this enzyme far exceeds the maximum dosage of CB1954. Due to these limitations, new enzymes are now being investigated for their potential use in directed enzyme prodrug therapy. One such enzyme that has proved promising is the YfkO nitroreductase from Bacillus Licheniformis. Upon investigation, the YfkO nitroreductase was shown to have a much lower Km (below the maximum dosage) than that of NfnB as well as the fact that when reacting with the prodrug it produces a much more favourable ratio of enzymatic products than NfnB, forming more of the desired 4-hydroxylamine derivative of CB1954.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	MDPI
ISSN:	1999-4923
Date of First Compliant Deposit:	11 November 2022
Date of Acceptance:	26 March 2021
Last Modified:	20 May 2023 11:36
URI:	https://orca.cardiff.ac.uk/id/eprint/154131

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item